Latest news with #CathieWood
Yahoo
13 hours ago
- Business
- Yahoo
This Preeminent Cryptocurrency Will Soar Nearly 2,200% in 5 Years, According to One of Wall Street's Most Famous Money Managers
Cathie Wood garnered attention following the outperformance of the Ark Innovation ETF in the wake of the 2020 COVID-19 stock market crash. A recently updated report from Wood's Ark Invest calls for Bitcoin to skyrocket to $2.4 million per token by 2030. However, numerous shortcomings for crypto's digital gold make a 50% decline far likelier than a 2,200% gain by the turn of the decade. 10 stocks we like better than Bitcoin › On Wall Street, optimism is something of the norm. Even though historical data tells us that not every stock is going to increase in value over the long run, there's a wide disparity among analysts between positive and negative ratings. Whereas 56% of all analyst ratings are the equivalent of "buy" on S&P 500 companies, according to Barron's, just 6% of all ratings fell on the sell side of the equation for S&P 500 companies, as of February. These ratings, while not always accurate, typically offer investors a baseline of how institutional investors and analysts view their company and/or America's most-influential businesses. But every so often, an issued price target by an analyst or financial pundit is so far above and beyond the current price of a security that it'll stop investors in their tracks. A little over five weeks ago, one of Wall Street's most famous money managers issued a report that, in the most bullish case scenario, called for the world's most preeminent cryptocurrency to soar by nearly 2,200% come 2030. While this report was littered with a half-dozen reasons to expect this "digital gold" to skyrocket over the next five years, I believe it's far likelier this digital currency will lose half (or more) of its value rather than tack on another 2,200%. Following the five-week COVID-19 crash in 2020, Ark Invest's CEO and Chief Investment Officer Cathie Wood made a name for herself on Wall Street. Wood's penchant for buying highly innovative companies and game-changing cryptocurrencies led to eye-popping returns in 2020 for Ark's flagship fund, the Ark Innovation ETF. While some of Wood's prognostications have been lofty, perhaps nothing tops her firm's recently updated forecast for the world's leading cryptocurrency, Bitcoin (CRYPTO: BTC). Previously, Wood had forecast a bull-case scenario of $1.5 million per token by 2027. But due to various factors, she now believes Bitcoin can ascend to $2.4 million in five years, which would represent upside of almost 2,200% as of this writing in the late evening of May 29, 2025. Ark Invest's extensive report lists six variables that, under the right circumstances, can send Bitcoin to the moon: An increase in institutional investment, which will be facilitated through spot Bitcoin exchange-traded funds (ETFs). Bitcoin being nimbler than physical gold makes it a more easily transferable and convenient store of value. Investors in emerging markets will seek out Bitcoin as a way to protect their money against the effects of inflation and currency devaluation. More foreign nations purchase or hold Bitcoin via a strategic reserve. Additional public companies choose to use their cash to purchase and hold Bitcoin as their asset reserves. Demand for Bitcoin-driven, on-chain financial services grows and begins to replace legacy financial services. While there's no denying that Bitcoin has proved skeptics wrong for more than a decade, there are counterarguments to be made to Wood's bullish thesis that make her $2.4 million price target by 2030 seem outlandish. For example, one of the leading reasons to buy Bitcoin is that it's a perceived hedge against inflation. With U.S. money supply growing on an almost constant basis for more than 150 years and Bitcoin's token supply capped at 21 million, it's viewed as a naturally scarcer asset. But this isn't entirely accurate. While it might be easier to transfer Bitcoin digitally between users than it is to exchange physical gold, the latter is a tangibly limited resource. Though we haven't mined all the gold in existence, we can't create more gold than currently exists on planet Earth. The same can't be said for Bitcoin, which is limited solely by lines of computer code and developer consensus. While it's unlikely that consensus will be reached to increase the supply of Bitcoin, the probability of it happening isn't 0%. Therefore, Bitcoin's scarcity is a false perception. I believe Cathie Wood is also incorrect in her assumption that emerging markets will seek out the world's leading digital currency to protect against inflation and currency devaluation. In September 2021, El Salvador became the first country to officially adopt Bitcoin as legal tender. The government purchased Bitcoin, as well as encouraged citizens to utilize this digital gold to pay for everyday items. Less than four years later, the country's real-world Bitcoin experiment has failed. Few of its citizens adopted the currency for practical use, and the inherent volatility in Bitcoin ran the risk of compromising El Salvador's financial stability. To build on this point, Bitcoin's first-mover competitive advantages are now effectively gone. While it's still the largest (by market value) and most well-known digital currency, Bitcoin's network is nowhere close to the fastest or the cheapest. A number of other popular blockchain projects can accomplish the on-chain financial services Wood speaks of far more efficiently than Bitcoin. Lastly, it's important to recognize the role investor sentiment and historical cycles play in an asset class that's not driven by much in the way of traditional fundamentals. Despite Bitcoin leaving the benchmark S&P 500 in the dust on a total return basis, cryptocurrencies are also known for their steep and long-winded bear markets. Over the last 15 years, Bitcoin has endured around a half-dozen declines of 50% or greater. This includes losing 99% of its value in June 2011, an 83% swoon following the Mt. Gox scandal in April 2013, an 84% tumble during the 2017 to 2018 crypto winter, and the loss of 75% of its value between November 2021 and December 2022. It can take years to recoup these emotion-driven moves lower in crypto's digital gold. History suggests it's far more likely Bitcoin will shed more than half of its value and head to $50,000 (or considerably lower) than it is that Cathie Wood's moonshot price target will prove accurate come 2030. Before you buy stock in Bitcoin, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Bitcoin wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $638,985!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $853,108!* Now, it's worth noting Stock Advisor's total average return is 978% — a market-crushing outperformance compared to 171% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of May 19, 2025 Sean Williams has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Bitcoin. The Motley Fool has a disclosure policy. This Preeminent Cryptocurrency Will Soar Nearly 2,200% in 5 Years, According to One of Wall Street's Most Famous Money Managers was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Insider
19 hours ago
- Business
- Business Insider
Cathie Wood Loses Confidence in Palantir Stock (PLTR) Ahead of Q1 Earnings
Cathie Wood's ARK Investment Management continues to trim holdings of Palantir (PLTR) ahead of the AI-driven data analytics firm's Q1 earnings, due on May 5. On May 2, ARK Invest disclosed selling $30.7 million worth of Palantir stock. Earlier on May 1, the investor reported a $2.65 million sale of PLTR shares. Protect Your Portfolio Against Market Uncertainty Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter. Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox. For those tracking ARK Invest's moves, ARK Invest has consistently held PLTR stock in multiple ETFs, showing Wood's strong belief in its data analytics and AI potential. Thus, the latest sales appear to be profit-taking, as Palantir stock has gained over 64% year-to-date, partly due to new defense contracts and expanding commercial applications. ARK Bets Big on Roku, GH, ABNB While selling PLTR, ARK Invest has increased its positions in other tech and healthcare companies. This shows a shift in capital toward areas with faster growth in the near future. On May 2, ARK doubled down on Roku (ROKU), buying 369,016 shares worth $24.8 million. With streaming competition heating up, Wood's bet suggests confidence in Roku's ability to maintain a strong position. Another major purchase was Guardant Health (GH), with ARK investing $20.5 million in the oncology-focused biotech firm. This aligns with ARK's long-term focus on precision medicine and AI-powered healthcare solutions. Also, Wood bought 49,560 shares of Airbnb (ABNB) valued at $6.1 million. The investment signals optimism in short-term rentals amid a strong travel rebound. Analysts' View Ahead of PLTR's Q1 Earnings Ahead of Q1 results, analysts expect Palantir to report earnings per share (EPS) of $0.13, up 62.5% from the prior-year quarter. Also, the company's revenue is expected to increase 35.9% to $862.17 million in the first quarter. While the projections show year-over-year growth, analysts remain less optimistic heading into Q1. Last week, RBC Capital analyst Rishi Jaluria reiterated a Sell rating on PLTR stock. Also, his price target of $4o implies a 67.8% downside potential from the current level. Is PLTR a Good Stock to Buy? Turning to Wall Street, analysts have a Hold consensus rating on Palantir stock based on two Buys, eight Holds, and three Sells assigned in the past three months. The average PLTR stock price target is $89.17, implying a downside potential of 28.25%.
Business Insider
20 hours ago
- Business
- Business Insider
TSMC Stock Maintains High-Conviction AI Play Status With $220 Price Target
Taiwan Semiconductor Manufacturing Company (TSM), or TSMC for short, the world's numero uno pure-play semiconductor foundry, has surged nearly 20% over the past month. Despite this impressive rally, my outlook remains bullish. Confident Investing Starts Here: The company is well-positioned to benefit from powerful tailwinds, including relentless AI-driven demand, a dominant—nearly monopolistic—position in advanced chip manufacturing, ongoing geographic diversification, and a steady cadence of technological breakthroughs. Unveiling Next-generation Technologies in the Coming Years TSMC continues to be the principal manufacturer and primary supplier of chips for leading AI powerhouses, including Nvidia (NVDA), Advanced Micro Devices (AMD), Apple (AAPL), and Qualcomm (QCOM). Notably, TSM is also the producer of Nvidia's cutting-edge Blackwell chip series, which has recently gained immense popularity. TSMC's 3nm process currently represents the most advanced semiconductor technology in the industry, delivering superior power efficiency and performance. Looking ahead, anticipation is building around the company's upcoming 2nm and 1.6nm nodes, scheduled for launch in late 2025 and 2026, respectively. The 2nm technology, referred to as N2, remains on track for volume production in the second half of 2025. This next-generation process is expected to deliver a 10–15% improvement in processing speed at the same power consumption, or a 20–30% reduction in power usage at equivalent performance. Following that, the 1.6nm process is projected to further improve power efficiency by an additional 15–20% over the 2nm node. These advancements are especially timely, as data centers grapple with rising energy costs. The shift to more power-efficient chips is becoming not only a technological imperative but also an economic necessity. This positions TSMC as a key enabler in the ongoing global semiconductor upgrade cycle. Reflecting this momentum, TSMC has outlined strong long-term growth expectations. The company projects its AI-related chip revenue to grow at a compound annual growth rate (CAGR) of 45% over the next five years, while overall revenue is forecast to grow at a 20% CAGR during the same period. These figures underscore the company's pivotal role in powering the future of computing. Such growth potential hasn't gone unnoticed. Famous investor Cathie Wood 's Ark funds recently purchased 241,047 shares of Taiwan Semiconductor, worth $46.3 million, signaling firm institutional conviction. TSM Has Unrivaled Market Leadership TSM commands an overwhelming 64.9% global market share in the foundry segment, dwarfing its closest competitors— Samsung Electronics (SMSN) and Intel (INTC), according to Statista. Its unparalleled scale, deep client relationships, and technological edge create formidable barriers to entry. This dominant position grants TSM significant pricing power. Clients, many of whom have relied on TSM for decades, are unlikely to switch suppliers given the risk of falling behind in the rapidly evolving AI race. One of the major risk factors associated with TSM is its geographical location in Taiwan, which poses the risk of a takeover by China. However, TSM is prioritizing geographic diversification as a core strategic initiative, proactively addressing these risks by diversifying its global manufacturing footprint. In addition to its $65 billion investment in U.S.-based fabs, TSM has committed a further $100 billion to expand capacity globally. Its Arizona facility is reportedly operating at full capacity through 2027, highlighting robust demand. This geographic diversification not only reduces exposure to potential tariffs but also strengthens TSM's resilience to geopolitical volatility. Beyond the U.S., TSM is also establishing a new chip design center in Munich, Germany, as well as a manufacturing plant in Dresden, Germany, and new fabs in Japan. Taiwan Semiconductor's strategic investments beyond its home base reflect prudent risk management and reinforce its strategic shift toward a more balanced global presence. Pre-Earnings Numbers Point to Positive Outlook for Upcoming Earnings TSM is set to report its Q2 2025 earnings on July 17. The company is projected to report earnings per share (EPS) of $2.30, representing a 57.5% year-over-year increase. Additionally, Q2 revenues are projected to increase by 13% year-over-year, ranging between $28.4 billion and $29.2 billion, driven by high demand for its advanced 3-nanometer (nm) and 5-nm processes. On May 9, TSM unveiled impressive revenue figures for April 2025, marking the highest ever figure in any single month in the company's history. April net revenues galloped 48.1% year-over-year to 349.6 billion New Taiwan dollars (approximately $11.6 billion). It's worth noting that TSM anticipates 24% to 26% sales growth for FY2025, driven by strong demand for its latest nanochips amid the AI surge. Importantly, TSM trades at an attractive valuation compared to its peers. In terms of its valuation, TSM looks cheap. Currently, it's trading at an attractive forward P/E ratio of 21x, compared to much higher multiples of its peer group. Semiconductor company Advanced Micro Devices is trading at a higher forward P/E multiple (28x), while the AI prodigy Nvidia is trading at a forward P/E of 32x. Is TSMC a Buy, Sell, or Hold? On Wall Street, TSM stock carries a Strong Buy consensus rating based on seven Buy, one Hold, and zero Sell ratings over the past three months. TSM's average stock price target of $219.43 implies approximately 11% upside potential over the next twelve months. The semiconductor industry continues to experience strong growth, driven largely by the rapid adoption of artificial intelligence technologies. TSMC, with its unmatched manufacturing capabilities, deeply embedded customer relationships, and advanced technology roadmap, is exceptionally well-positioned to capitalize on this transformative trend. The company's timely investments in next-generation nodes—specifically 2nm and 1.6nm—alongside its global manufacturing expansion, align well with rising demand fueled by a broad upgrade cycle across the tech landscape. These factors collectively make TSMC a compelling long-term investment opportunity. With a favorable valuation and strong earnings momentum, the current environment presents an attractive entry point for investors looking to gain exposure to the accelerating AI megatrend.
Yahoo
a day ago
- Business
- Yahoo
Why Tempus AI Stock Plummeted This Week
Tempus AI is a healthcare-oriented artificial intelligence company. Spruce Point Capital Management released a report critical of Tempus AI this week. Investors should exercise caution with Tempus AI stock but not be deterred from considering an investment solely based on the critical report. 10 stocks we like better than Tempus Ai › Extending the more-than-4% slide that they experienced last week, shares of Tempus AI (NASDAQ: TEM) have suffered an even more precipitous decline this week. According to data provided by S&P Global Market Intelligence, the healthcare-oriented artificial intelligence (AI) stock had fallen 13.2% from the end of last Friday's trading session through the market's close on Thursday. The stock's decline can be singularly attributed to a critical report of the company that a short-seller provided on Wednesday. Arguing that investors should be circumspect about the company's financials and its public claims, Spruce Point Capital Management provided the market with a report that questions the credibility of Tempus AI. In addition to questioning the integrity of the company's founder, Eric Lefkofsky, Spruce Point raised doubts about Tempus AI's financial reporting and the nature of its partnership with AstraZeneca -- among other issues. Based on its analysis, Spruce Point stated that Tempus AI stock has the potential to fall about 50% to 60%. From the stock's closing price on Tuesday (the day before Spruce Point released its report), this implies a stock price of $26.35 to $32.94. Founded in 2009, Spruce Point is an investment management firm that focuses on short-selling opportunities. Since Spruce Point stands to profit from Tempus AI stock falling, investors should take its claims with a heaping tablespoon of salt. While it raises some strong accusations against the company, Tempus' supporters are unmoved. Ark Invest, led by Tempus AI bull Cathie Wood, for example, bought 251,080 shares of Tempus AI on Wednesday. At this point, potential investors will want to exercise caution and see how the company responds. Before you buy stock in Tempus Ai, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Tempus Ai wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $638,985!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $853,108!* Now, it's worth noting Stock Advisor's total average return is 978% — a market-crushing outperformance compared to 171% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of May 19, 2025 Scott Levine has no position in any of the stocks mentioned. The Motley Fool recommends AstraZeneca Plc. The Motley Fool has a disclosure policy. Why Tempus AI Stock Plummeted This Week was originally published by The Motley Fool
Cision Canada
a day ago
- Business
- Cision Canada
Real-World Deployments Signal AI Healthcare Is Ready for Scale
Issued on behalf of Avant Technologies Inc. VANCOUVER, BC, May 30, 2025 /CNW/ -- The concept of AI in healthcare is no longer a novelty, experts are acknowledging AI algorithms, detection, and drug discovery are becoming indispensable tools. As medical errors continue to harm patients, healthcare experts are turning to AI to improve mistakes in medications, such as prescribing the wrong drug or wrong dose. As real-world deployment gains momentum, a number of tech and biotech firms are already translating AI healthcare innovation into clinical practice. Notable recent activity includes initiatives from Avant Technologies, Inc. (OTCQB: AVAI), Tempus AI, Inc. (NASDAQ: TEM), BioXcel Therapeutics, Inc. (NASDAQ: BTAI), Healwell AI Inc. (TSX: AIDX) (OTCPK: HWAIF), and WELL Health Technologies Corp. (TSX: WELL) (OTCQX: WHTCF). Cathie Wood of Ark Invest recently highlighted new research from Mass General Brigham, where AI models were able to predict cancer survival outcomes based on facial images—an example she cited as evidence that healthcare could become AI's most transformative use case. Industry forecasts support that trajectory, with Statista estimating that the global AI healthcare market will grow from roughly $11 billion today to $188 billion by 2030, reflecting a compound annual growth rate of 37%. Avant Technologies, Inc. (OTCQB: AVAI), in collaboration with Ainnova Tech, is quietly building a foothold in the emerging field of predictive diagnostics. Its Vision AI platform is designed to identify disease markers at the earliest possible stage—sometimes before outward symptoms emerge—by leveraging artificial intelligence in combination with clinical data. In its latest move, Avant disclosed plans to integrate a patented technology that targets early-stage dementia detection, signaling an intentional broadening of its preventive care focus. The proposed tool uses proprietary algorithms alongside hardware and a five-minute blood test to flag dementia-associated risk factors well in advance of standard clinical methods. Avant is weighing both licensing and acquisition options for the technology, with global rights under consideration. Either route would strengthen the company's position in the neurodegenerative care space and complement its broader push into chronic illness screening. By expanding its platform's range without departing from its central thesis—early, accessible intervention— Avant is quietly aiming to reshape how and when critical conditions are first detected. "This accessible, fast, and scalable solution is designed to support early intervention and targeted treatment strategies, with the ambition of reaching millions of patients globally in the coming years," said Vinicio Vargas, CEO at Ainnova and member of the Board of Directors of the joint venture company, Ai-nova Acquisition Corp. (AAC). "Adding the early detection of dementia that this patented technology presents us would go a long way to making us a leader in the industry of early disease detection." Vision AI is designed as a non-invasive platform that brings together retinal imaging, blood pressure readings, and routine lab data to generate personalized health assessments. Its core function is to estimate risk for common but often underdiagnosed chronic conditions—helping clinicians make earlier, more informed decisions with minimal burden on the patient. By analyzing just two retinal images and a short set of vital signs, the system runs four proprietary algorithms trained on more than 2.3 million clinical records. These algorithms evaluate indicators linked to cardiovascular disease, type 2 diabetes, liver fibrosis, and chronic kidney disease. The technology's lightweight, modular design is intended to keep costs low while enabling use across a wide range of clinical settings—including those with limited access to specialist care. "Our purpose is to create the future of early disease detection in an accessible way, so that patients can get a preventive check-up anywhere, at a low cost, and easily," said Vargas in a previous statement. "We want to prevent patients with risk factors from developing other diseases that could have been avoided before they became a real problem. To this end, we are seeking to integrate new technologies into our portfolio within a single platform, both through our R&D efforts and through potential exclusive licenses or acquisitions." Alongside its dementia screening initiative, Avant is progressing toward a full acquisition of Ainnova Tech, its current development partner. The two firms are already operating under a shared entity— Ai-nova Acquisition Corp. (AAC) —and a completed merger would align leadership, simplify corporate structure, and create a more efficient framework for navigating regulatory milestones. A key FDA pre-submission meeting is scheduled for July, making the timing of this integration especially relevant. Internally, management views the consolidation as a strategic lever to accelerate U.S. market access while continuing to support ongoing deployments in international pilot programs. "This milestone reflects our two-tiered strategy, rapid deployment in low-regulation markets where Vision AI operates as a screening tool, and simultaneous progress toward FDA clearance for the U.S. market," said Vargas. "Entering the U.S. will unlock significant commercial potential, and early engagement with regulators ensures we do so with speed, credibility, and a validated product." While many AI-driven diagnostic platforms remain confined to controlled pilots or lab settings, Avant's Vision AI is already operating in live clinical environments across Latin America. Active deployments in Chile, Mexico, and Brazil are generating real-world data on safety, performance, and clinical usability—insights that are feeding directly into iterative improvements across the platform. Longer term, the company aims to unify a growing range of diagnostic tools under a single, streamlined system capable of delivering early-stage health insights from basic, non-invasive inputs. Backed by global platform rights through AAC, and supported by detection sensitivity levels reported above 90% in research cited by the NIH, Vision AI is quietly shaping into a scalable solution with potential utility across both developed and underserved healthcare systems. With dementia screening now entering the pipeline and additional modules under evaluation, Avant appears to be transitioning from early validation to broader execution—laying the groundwork for international expansion and a future U.S. launch. Tempus AI, Inc. (NASDAQ: TEM) has reached a major milestone, having supported close to 1,500 research projects since its founding in 2015. These efforts include around 1,000 biopharma partnerships and nearly 500 provider-led initiatives using Tempus' diagnostics, datasets, and modeling tools. The company's biological modeling lab alone has contributed to over 60 research projects focused on therapy selection and drug discovery. "From day one at Tempus, our mission has been to empower researchers with the data and insights they need to drive better outcomes," said Eric Lefkofsky, Founder and CEO of Tempus. "We have made significant progress toward that goal by delivering at a scale few others have achieved." With one of the largest libraries of multimodal data in healthcare, Tempus continues to scale its impact through AI-driven precision medicine. An independent safety board has endorsed the continuation of BioXcel Therapeutics, Inc.'s (NASDAQ: BTAI) pivotal Phase 3 SERENITY At-Home trial evaluating BXCL501 for agitation tied to bipolar disorders or schizophrenia. "We are pleased with the favorable DSMB meeting outcome and are excited about the upcoming data readout for our first at-home trial with BXCL501," said Vimal Mehta, Ph.D., CEO of BioXcel Therapeutics. "Results are intended to help support a potential sNDA submission for label expansion of IGALMI® in the at-home setting — a sizeable unmet medical need given there are no FDA -approved therapies for bipolar or schizophrenia-related agitation in this environment." The fully enrolled trial involves over 200 patients who self-administer treatment during agitation episodes, with safety data tracked over 12 weeks. More than 150 participants have already received multiple doses. Topline results are slated for release in the third quarter of 2025 and may inform a future regulatory submission. Three subsidiaries under Healwell AI Inc. (TSX: AIDX) (OTCPK: HWAIF) and WELL Health Technologies Corp. (TSX: WELL) (OTCQX: WHTCF) have been selected as winners in Canada Health Infoway's 2025 Vendor Innovation Program, making up nearly half of the total awardees. The selected projects—Pentavere, Intrahealth, and OceanMD—are focused on real-world interoperability solutions that improve clinical workflows and enhance access to actionable patient data. "Intrahealth and Pentavere's recognition through the Vendor Innovation Program demonstrates the tremendous impact HEALWELL companies are having in the digital health landscape," said Dr. Alexander Dobranowski, CEO of HEALWELL. "Both companies are at the forefront of transforming healthcare delivery with innovative solutions that enhance data-driven care coordination, streamline workflows, and empower clinicians to deliver better patient outcomes." Each initiative will be deployed across multiple provinces and settings, including rural and Indigenous communities. "We are incredibly proud to see OceanMD, as part of WELLSTAR, recognized for its innovation in improving healthcare outcomes through digital technologies," said Amir Javidan, CEO of WELLSTAR — a subsidiary of WELL Health that focuses on digital health innovation and owns OceanMD, one of the three selected projects in the Vendor Innovation Program. "This recognition is a testament to the exceptional work our team is doing in transforming patient care, and we are excited to see the impact this will have in clinical settings across Canada." This recognition highlights both companies' leadership in advancing digital healthcare infrastructure in Canada. DISCLAIMER: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. Equity Insider is a wholly-owned subsidiary of Market IQ Media Group, Inc. ("MIQ"). MIQ has been paid a fee for Avant Technologies Inc. advertising and digital media from the company directly. There may be 3rd parties who may have shares Avant Technologies Inc., and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of MIQ own shares of Avant Technologies Inc. which were purchased in the open market. MIQ reserves the right to buy and sell, and will buy and sell shares of Avant Technologies Inc. at any time thereafter without any further notice. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material disseminated by MIQ has been approved by the above mentioned company; this is a paid advertisement, and we own shares of the mentioned company that we will sell, and we also reserve the right to buy shares of the company in the open market, or through other investment vehicles. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.
